Role of new serological markers in evaluating the progression of liver disease in patients with chronic HBV infection and normal aminotransferases / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 644-650, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-971907
ABSTRACT
Antiviral therapy is the basic treatment method for improving prognosis recommended in the management guidelines of chronic hepatitis B in China and globally. For patients with chronic HBV infection and normal transaminases, it is difficult in clinical practice to accurately evaluate the progression of hepatitis and identify suitable patients who need antiviral therapy. In order to objectively and accurately evaluate the degree of liver inflammatory activity in such patients, more and more noninvasive evaluation indicators have been used in addition to conventional liver biopsy. This article reviews the new serological indicators that can reflect the degree of liver inflammation and/or fibrosis in patients with chronic HBV infection and normal aminotransferase levels, hoping to provide a reference for antiviral decision-making in these patients.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Clinical Hepatology
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS